Angiocrine Bioscience

Executive Summary

Angiocrine Bioscience is a San Diego-based private biotechnology company pioneering cellular therapies for tissue repair and regeneration using its proprietary E-CEL (Endothelial Co-culture Expanded Cells) platform. Founded in 2009, the company leverages endothelial co-culture to expand therapeutic cells, aiming to restore function in damaged tissues and organs. Though early-stage and under the radar, Angiocrine's approach has potential in regenerative medicine, particularly for vascular and ischemic conditions. The company lacks publicly disclosed pipeline candidates or funding details, limiting visibility into its near-term prospects. However, its novel platform could attract partnerships or licensing deals as it advances toward clinical validation.

Upcoming Catalysts (preview)

• Q4 2026Partnership or licensing agreement with a larger biotech or pharma company50% success
• Q2 2027IND filing or clinical trial initiation for lead E-CEL candidate35% success
• Q3 2026Publication of preclinical proof-of-concept data in a peer-reviewed journal60% success